Targeted Genomics demand CooperGenomics operates in reproductive genetics with PGT-A, PGT-M, PGT-SR and ERPeak endometrial testing, suggesting strong opportunities to cross-sell complementary genetic testing services and expand into adjacent embryo testing markets with clinics and fertility centers.

Mid-market scale With 51-200 employees and annual revenue in the 25–50 million range, CooperGenomics sits in a mid-market tier ideal for enterprise partnerships, channel programs, and ROI-focused collaborations with midsize fertility clinics and regional hospitals seeking scalable genetic testing solutions.

Family of CooperSurgical Being part of the CooperSurgical family positions CooperGenomics for bundled offerings, co-marketing, and leverage of an established customer base in reproductive health to accelerate upsell of test menus and value-added services.

Digital and payments readiness Existing tech stack includes Stripe and Cloudflare bot protection, indicating readiness for secure online ordering, subscription-like service models, and streamlined customer onboarding—opportunities to pitch self-serve portals, automated invoicing, and enhanced analytics for clinics.

Competitive positioning Revenue range aligns with peers like Counsyl and AIVITA in niche reproductive genetics; potential sales angles include expanding high-value PGT offerings to clinics seeking comprehensive genetic testing portfolios and differentiated endometrial receptivity assessments.